S&P 500 gains to extend record run, set for positive week
Kirsten Marriner, Executive Vice President and Chief People Officer at Clorox Co . (NYSE:CLX), has recently sold shares of the company’s common stock, according to a Form 4 filing with the Securities and Exchange Commission. The $18.13 billion market cap company, which currently trades at a P/E ratio of 40x, has maintained a strong financial health score according to InvestingPro analysis. The transactions, which took place on March 10 and 11, involved the sale of a total of 8,227 shares at prices ranging from $150.00 to $153.4606 per share. The total value of these sales amounted to approximately $1.25 million. Notably, Clorox has demonstrated strong shareholder returns, maintaining dividend payments for 55 consecutive years with a current yield of 3.29%.
Following these transactions, Marriner retains ownership of 26,305 shares of Clorox stock. The sales were executed as part of a pre-planned trading program under Rule 10b5-1, which allows company insiders to set up a predetermined plan for selling stocks in accordance with insider trading laws. For detailed analysis and additional insights, including 7 more exclusive ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Clorox reported its second-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $1.55, compared to the forecasted $1.39. Revenue also exceeded projections, reaching $1.69 billion against the anticipated $1.63 billion. The company has increased its full-year 2025 EPS guidance by 5%, attributing this adjustment to anticipated retailer pre-buying ahead of its Enterprise Resource Planning (ERP) system implementation. This change is expected to shift approximately $0.35 of EPS from the first half of fiscal year 2026 to the fourth quarter of fiscal year 2025.
Analysts have had varied responses to Clorox’s performance. DA Davidson adjusted its price target on Clorox shares to $169 from $171, maintaining a Neutral stance. Goldman Sachs reiterated a Sell rating with a steady price target of $138, citing ongoing challenges despite some positive developments. Conversely, Jefferies raised its price target to $189, maintaining a Buy rating, highlighting Clorox’s ability to surpass projections and adjust guidance optimistically. Citi also adjusted its price target to $165 from $175, keeping a Neutral stance, reflecting cautious optimism about Clorox’s near-term performance but anticipating potential headwinds in fiscal year 2026. These developments underscore the mixed analyst outlook on Clorox’s future performance amid its ongoing operational transitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.